In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive care options, covering treatments for acute myeloid leukemia (AML), ...

For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...

According to Nova One Advisor, the global exosome research market size is calculated at USD 225.72 million in 2025 and is ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.